Nina Cao is an associate in the Corporate & Securities practice in Mayer Brown’s New York office. Nina’s practice focuses on mergers and acquisitions, venture capital and PE deals, as well as other corporate transactions, across a variety of industries, including renewable energy, chemical, biomedical, pharmaceuticals and real estate. She advises clients in US and cross-border acquisitions, reorganizations, joint ventures, strategic alliances, commercial transactions and general corporate matters.

Prior to joining Mayer Brown, Nina worked in the Corporate and M&A group in one of China’s most prestigious and largest law firms in its New York office as a senior associate. Her practice focused on M&A, PE and VC investments.


M&A/Joint Ventures/Venture Capital Investments:

  • Represented a subsidiary of KKR & CO. Inc. in the sale of 100% of the equity interests in a 1,171 MWac operating solar portfolio consisting of 11 projects in 8 states.
  • Represented a financial investor in its acquisition of the equity interests in multiple project companies for the development and construction of an aggregate of 55.0 MWac portfolio of solar-powered electricity generating plants.
  • Represented The Jordan Company in its acquisition through a newly formed company of four global business segments of Trimble Inc.: Protempis, a timing and synchronization solutions company; Loadrite, a weighing solutions company; Spectra Precision, a manufacturer of precision laser instruments; and SECO, a surveying equipment and instruments provider.
  • Represented Yixing Capital in its acquisition of global furniture company Lexington Home Brands, Inc.
  • Represented Joinn Laboratories China Co. Ltd. in its acquisition of Biomedical Research Models, a Boston-based pre-clinical CRO.
  • Represented Tsingshan Group in its acquisition of the DRAP business line of Allegheny Technologies Incorporated (NYSE: ATI) by forming a joint venture.
  • Represented a global maritime company in its strategic acquisitions of a majority stake in three Indian aquatic products processing companies.
  • Represented a private equity fund in its acquisition of an Alabama-based molecular diagnostic company.
  • Represented ZTE Corporation in its acquisition of a controlling stake in a California-based commercial physical and biological research company.
  • Represented a California software system designing and development company in its venture capital financing, restructuring and re-domiciliation to Cayman Islands through a reverse triangular merger.
  • Represented a group of private equity funds in their joint acquisition of a California-based video producing company.
  • Represented a global private equity firm in its serial investments in numerous biotechnology companies across the US
  • Represented Thalys Medical Technology Group in its investment in LevitasBio, a Stanford spinout commercializing a cell purification and separation technology based on magnetic levitation.
  • Represented a Chinese publicly listed biotech pharmaceutical company in its investment in a Maryland-based therapeutical company.
  • Represented a Chinese publicly listed medical equipment manufacturing and distributing company in its investment in a California-based molecular diagnostics company.


Washington University in St. Louis, JD


  • New York